Intense Market Competition: The liquid biopsy and precision oncology market is highly competitive, with established diagnostic companies, large pharmaceutical firms, and numerous startups vying for market share. Competitors may develop more effective, less costly, or more widely adopted tests, potentially eroding Guardant Health's market position.

Regulatory Approval Hurdles: Guardant Health's products require rigorous regulatory approvals, primarily from the FDA in the U.S. The approval process is lengthy, expensive, and uncertain, with potential for delays or outright rejections that could significantly impact market entry and commercialization.

Reimbursement Challenges: Securing favorable reimbursement policies from government payers (e.g., Medicare) and private insurers is crucial for commercial success. Unfavorable coverage decisions, delays in payment, or reductions in reimbursement rates could severely constrain revenue growth and profitability.